JEGS Automotive to Showcase Race Cars at the New James

June 28, 2013

COLUMBUS, Ohio – Race car drivers with JEGS Automotive Inc. will pass out 1,500 homemade cookies and meet with construction workers helping to build the new James Cancer Hospital and Solove Research Institute at The Ohio State University Wexner Medical Center during a private event at 2 p.m. Tuesday. Media are invited to cover the event in the parking lot on W. 10th Ave., in front of the new cancer hospital.

Construction workers will have their photos taken with the drivers and race cars operated by the Coughlin family, which owns JEGS Automotive, one of the largest and most successful automotive equipment companies in the nation and a record-breaking racing team.

The event will enable the Coughlin family -- including Jeg Coughlin Sr. and sons John, Troy, Mike, and Jeg Jr. – along with the drivers and their crews, to personally thank the construction workers for their efforts to create a cancer-free world with the new 300+-bed cancer hospital, slated to open in 2014.

The Coughlins recently gave $10 million to The Ohio State University Foundation to help transform cancer treatment and research at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC–James).

In June, Ohio State’s Board of Trustees recognized the gift and approved naming the main first-floor lobby of the new James in honor of the JEGS Foundation.

The Coughlin family features the JEGS Racing for Cancer Research ribbon on all race cars and uniforms to raise awareness. The logo is a ribbon bearing the black and white checkered motif of a finish line flag, filled in with colors representing various cancer awareness programs.

The OSUCCC – James strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment.

Ohio State is one of only 41 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only four centers funded by the NCI to conduct both phase I and phase II clinical trials. As the cancer program’s 228-bed adult patient-care component, The James is a “Top Hospital” as named by the Leapfrog Group and one of the top cancer hospitals in the nation as ranked by U.S. News & World Report.

# # #

Click here for a high-quality photograph of the new James Cancer Hospital and Solove Research Institute under construction at The Ohio State University Wexner Medical Center.

Click here for a high-quality rendering of the new lobby of the James Cancer Hospital and Solove Research Institute under construction at The Ohio State University Wexner Medical Center.

Click here for a high-quality photo of the Coughlin family. Jeg Coughlin, Sr., founder of JEGS Automotive Inc., (seated) is surrounded by his sons who now own the business, (from left) John, Troy, Mike and Jeg Jr.

Click here for a high-quality photo of the JEGS Foundation Racing For Cancer Research ribbon.

Media Contacts:

Eileen Scahill, Wexner Medical Center Public Affairs and Media Relations, 614-293-3737, or

Scott “Woody” Woodruff, JEGS Foundation, 614-595-1820 or

Contact Media Staff

Amanda Harper

Director of Media Relations

614-685-5420 (direct)

614-293-3737 (main)

Media staff are available by calling 614-293-3737 Monday through Friday between 8 a.m. and 5 p.m.


If after hours, please call 614-293-8000 (ask the operator to page the hospital administrative manager).

Latest News

New Procedures at The James Ease Lymphedema's Pain

On this week’s Toward a Cancer-Free World, nationally acclaimed Plastic & Reconstructive Surgeon Dr. Roman Skoracki explains how two brand new procedures now available at The James can help stop...

Read More

Prostate Cancer Androgen Receptor Activates a Different Gene Set When Bound to Antiandrogens

The androgen receptor in prostate cancer cells can activate different sets of genes depending on whether it binds with an androgen hormone or an antiandrogen drug, according to a new study led by...

Read More